News

Airbus Dominates Jet Deliveries with 766 in 2024, Outpacing Rivals

Airbus Dominates Jet Deliveries with 766 in 2024, Outpacing Rivals

Airbus Secures Its Leading Position in Jet Deliveries

Airbus delivered a remarkable total of 766 airliners in 2024, solidifying its status as the frontrunner in the global jetmaking industry for the sixth consecutive year. As Boeing continues to recover from significant internal challenges, Airbus's accomplishments shine brightly against the backdrop of an evolving aviation landscape.

Close Call with Delivery Targets

While Airbus slightly missed its target of delivering around 770 jets, this figure represents a strategic move considering ongoing interruptions within global supply chains due to parts and labor shortages. This proactive approach allowed Airbus to manage expectations effectively during a time of logistical difficulties.

Analyzing Growth Rates During Recovery

The deliveries in 2024 indicate a gradual slowdown in Airbus’s post-pandemic recovery, with industrial growth dropping to 4% compared to an impressive 11% growth in the prior year. This shift reflects broader market challenges that the aviation sector faces amidst ongoing recovery efforts.

Boeing's Journey Towards Recovery

Although Boeing has yet to release its annual delivery statistics, the company is navigating its way back from a prolonged internal crisis. The gap between Boeing and Airbus deliveries for 2024 appears significant, particularly in light of recent regulatory hurdles that have arisen following safety issues associated with some of its aircraft.

The Competitive Landscape Between Airbus and Boeing

Despite these setbacks, analysts emphasize that competition between Airbus and Boeing remains fierce. Both companies are aggressively pursuing new orders, striving to capture a larger share of the aviation market.

Order Book Insights for Airbus and Boeing

In terms of new orders, Airbus recorded a total of 878 gross orders, leading to a net total of 826 after accounting for cancellations. This figure represents a significant decline of 61% compared to the record numbers experienced in 2023. Meanwhile, as of the end of November, Boeing reported 370 net orders, emphasizing the challenges it currently faces.

Conclusion: Airbus's Dominance Endures

In summary, Airbus’s strong performance in 2024, with 766 jet deliveries, reaffirms its position at the top of the aviation industry. As it continues to navigate supply challenges alongside competitive pressures, the company remains a pivotal player in shaping the future of commercial aviation.

Frequently Asked Questions

What was the total number of jets delivered by Airbus in 2024?

Airbus delivered a total of 766 jets in 2024.

Did Airbus meet its delivery target for 2024?

Airbus fell short of its target of around 770 jets but managed to deliver a solid number under challenging conditions.

How does Airbus's growth rate compare to 2023?

The company's growth rate decreased from 11% in 2023 to 4% in 2024.

What is Boeing's current status in the market?

Boeing is cautiously recovering from an internal crisis and has reported 370 net orders as of late November.

Is the competition between Airbus and Boeing still active?

Yes, both manufacturers are actively competing for new orders despite their current challenges.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading

Top 5 Most Recently Viewed Articles

Kohat University Teams Up with MindHYVE.ai for AI Learning

Updated Category News Views 283

Kohat University Partners with MindHYVE.ai to Innovate Education In a significant advancement for higher education in the region, Kohat University of Science & Technology (KUST) has established a strategic partnership with MindHYVE.ai™. This collaboration aims to introduce ArthurAI™, an advanced learning platform that utilizes agentic AI technology, into its academic...

Continue Reading
Lulus Enhances Market Reach Through Innovative Collaborations

Updated Category News Views 336

Expanding Market Reach Through Strategic Collaborations LOS ANGELES, A prominent player in the fashion industry, Lulus is taking significant steps to enhance its market presence and reach customers in new and exciting ways. By initiating collaborations with various platforms, Lulus is keen on tapping into emerging retail channels and broadening its accessibility....

Continue Reading
Explore Top Gardening Trends for Fall by Calloway's Nursery

Updated Category News Views 172

Embracing Fall Gardening Trends with Calloway's Nursery As the seasons change, so does the opportunity to refresh our gardens and outdoor spaces. Calloway's Nursery is here to help you embrace the beauty of fall gardening. The nursery’s offerings are tailored to inspire Texans to create vibrant and inviting spaces. Fantastic Fall Container Gardens Container gardens are...

Continue Reading
happyactually Strengthens Leadership with Dr. Andia Shahzadi

Updated Category News Views 119

happyactually Appoints Dr. Andia Shahzadi as Chief Medical Officer happyactually, an innovative wellbeing technology firm, proudly announces the elevation of Dr. Andia Shahzadi to the position of Chief Medical Officer and Founding Member of the team. This change marks a significant step in the company's aim to empower life-conscious individuals through scientifically...

Continue Reading
Surrozen to Showcase Innovations at Investor Conference Soon

Updated Category News Views 76

Surrozen Announces Presentation at Healthcare Investor Conference Recently, Surrozen, Inc. (Nasdaq: SRZN), a pioneering biotechnology company based in South San Francisco, revealed that its management team will be presenting at an upcoming healthcare investor conference. The company specializes in targeted therapeutics that focus on selectively modulating the Wnt pathway,...

Continue Reading